Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1959 1
1960 2
1961 1
1962 2
1964 5
1965 4
1966 6
1968 6
1969 11
1970 3
1971 4
1972 5
1973 9
1974 7
1975 16
1976 21
1977 23
1978 21
1979 25
1980 28
1981 37
1982 57
1983 91
1984 145
1985 219
1986 303
1987 419
1988 582
1989 634
1990 763
1991 829
1992 869
1993 857
1994 800
1995 899
1996 852
1997 872
1998 825
1999 829
2000 876
2001 942
2002 853
2003 938
2004 921
2005 940
2006 951
2007 990
2008 1026
2009 1052
2010 1093
2011 1190
2012 1265
2013 1393
2014 1378
2015 1354
2016 1211
2017 1159
2018 1129
2019 1156
2020 1253
2021 1242
2022 1182
2023 263
Text availability
Article attribute
Article type
Publication date

Search Results

33,899 results
Results by year
Filters applied: . Clear all
Page 1
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund Å, Idicula T, Aamodt AH, Lund C, Næss H, Waje-Andreassen U, Thomassen L. Logallo N, et al. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2. Lancet Neurol. 2017. PMID: 28780236 Clinical Trial.
We aimed to investigate the safety and efficacy of tenecteplase versus alteplase in patients with acute stroke who were eligible for intravenous thrombolysis. ...By 3 months, 29 (5%) patients had died in the tenecteplase group compared with 26 (5%) in the alteplase …
We aimed to investigate the safety and efficacy of tenecteplase versus alteplase in patients with acute stroke who were eligible for …
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. Parsons M, et al. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842. N Engl J Med. 2012. PMID: 22435369 Free article. Clinical Trial.
BACKGROUND: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. ...
BACKGROUND: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mu …
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Huang X, et al. Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26. Lancet Neurol. 2015. PMID: 25726502 Clinical Trial.
BACKGROUND: In most countries, alteplase given within 4.5 h of onset is the only approved medical treatment for acute ischaemic stroke. ...FINDINGS: Between Jan 1, 2012, and Sept 7, 2013, 355 patients were screened, of whom 157 were eligible for intravenous thrombolysis, a …
BACKGROUND: In most countries, alteplase given within 4.5 h of onset is the only approved medical treatment for acute ischaemic strok …
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, Yan B, Valente M, Sharobeam A, Balabanski AH, Dos Santos A, Ng JL, Yogendrakumar V, Ng F, Langenberg F, Easton D, Warwick A, Mackey E, MacDonald A, Sharma G, Stephenson M, Smith K, Anderson D, Choi P, Thijs V, Ma H, Cloud GC, Wijeratne T, Olenko L, Italiano D, Davis SM, Donnan GA, Parsons MW; TASTE-A collaborators. Bivard A, et al. Lancet Neurol. 2022 Jun;21(6):520-527. doi: 10.1016/S1474-4422(22)00171-5. Epub 2022 May 4. Lancet Neurol. 2022. PMID: 35525251 Clinical Trial.
Five (9%) patients allocated to tenecteplase and five (10%) patients allocated to alteplase died from any cause at 90 days (aOR 1.12, 95% CI 0.26-4.90; p=0.88). ...Up to day 90, 13 serious adverse events were noted: five (5%) in patients treated with tenecteplase, and eigh …
Five (9%) patients allocated to tenecteplase and five (10%) patients allocated to alteplase died from any cause at 90 days (aOR 1.12, …
Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis.
Thelengana A, Radhakrishnan DM, Prasad M, Kumar A, Prasad K. Thelengana A, et al. Acta Neurol Belg. 2019 Sep;119(3):359-367. doi: 10.1007/s13760-018-0933-9. Epub 2018 May 4. Acta Neurol Belg. 2019. PMID: 29728903
Tenecteplase is a product of genetic modification of recombinant tissue plasminogen activator with superior pharmacodynamic and pharmacokinetic properties. ...Other outcomes did not differ between the tenecteplase and alteplase groups. Trials of cost-e …
Tenecteplase is a product of genetic modification of recombinant tissue plasminogen activator with superior pharmacodyn …
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.
Kheiri B, Osman M, Abdalla A, Haykal T, Ahmed S, Hassan M, Bachuwa G, Al Qasmi M, Bhatt DL. Kheiri B, et al. J Thromb Thrombolysis. 2018 Nov;46(4):440-450. doi: 10.1007/s11239-018-1721-3. J Thromb Thrombolysis. 2018. PMID: 30117036 Review.
Tenecteplase is a genetically mutated variant of alteplase with superior pharmacodynamic and pharmacokinetic properties. ...Hence, we conducted a study to evaluate the efficacy and safety of tenecteplase compared with alteplase in acute ischemic stroke. Electronic d …
Tenecteplase is a genetically mutated variant of alteplase with superior pharmacodynamic and pharmacokinetic properties. ...Hence, we …
Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P, Kim LJ, Mayer SA, Sheth KN, Schwamm LH; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Yaghi S, et al. Stroke. 2017 Dec;48(12):e343-e361. doi: 10.1161/STR.0000000000000152. Epub 2017 Nov 2. Stroke. 2017. PMID: 29097489 Review.
The document sections were divided among writing group members who performed the literature review, summarized the literature, and provided suggestions on the diagnosis and treatment of patients with sICH caused by systemic thrombolysis with alteplase. Several drafts were …
The document sections were divided among writing group members who performed the literature review, summarized the literature, and provided …
Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.
Burgos AM, Saver JL. Burgos AM, et al. Stroke. 2019 Aug;50(8):2156-2162. doi: 10.1161/STROKEAHA.119.025080. Epub 2019 Jul 18. Stroke. 2019. PMID: 31318627 Free article.
Background and Purpose- TNK (tenecteplase), a newer fibrinolytic agent, has practical delivery advantages over ALT (alteplase) that would make it a useful agent if noninferior in acute ischemic stroke treatment outcome. ...
Background and Purpose- TNK (tenecteplase), a newer fibrinolytic agent, has practical delivery advantages over ALT (alteplase) that w …
Tenecteplase versus alteplase after acute ischemic stroke at high age.
Thommessen B, Næss H, Logallo N, Kvistad CE, Waje-Andreassen U, Ihle-Hansen H, Ihle-Hansen H, Thomassen L, Morten Rønning O. Thommessen B, et al. Int J Stroke. 2021 Apr;16(3):295-299. doi: 10.1177/1747493020938306. Epub 2020 Jul 6. Int J Stroke. 2021. PMID: 32631157 Clinical Trial.
In the present study, the aim was to compare efficacy and safety of tenecteplase and alteplase in patients 80 years. METHODS: Data from the Norwegian Tenecteplase Stroke Trial, a randomized controlled trial comparing alteplase and tenecteplase, were assessed. ...Aft …
In the present study, the aim was to compare efficacy and safety of tenecteplase and alteplase in patients 80 years. METHODS: Data fr …
Alteplase (Cathflo Activase).
Middleton G, Ruzevick B. Middleton G, et al. Clin J Oncol Nurs. 2004 Aug;8(4):417-8, 420. doi: 10.1188/04.CJON.417-418. Clin J Oncol Nurs. 2004. PMID: 15354930 Review. No abstract available.
33,899 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "alteplase"